Metafuni Elisabetta, Giammarco Sabrina, De Ritis Daniela Giovanna, Rossi Monica, De Michele Teresa, Zuppi Cecilia, Bacigalupo Andrea P, Sica Simona, Chiusolo Patrizia
Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Università Cattolica del Sacro Cuore, Largo Gemelli 8, 00168, Rome, Italy.
Ann Hematol. 2017 Jun;96(6):929-933. doi: 10.1007/s00277-017-2974-1. Epub 2017 Mar 14.
Gastrointestinal graft-versus-host disease (GvHD) represents a life-threatening complication after stem cell transplantation. Differential diagnosis between gut GvHD and other causes of diarrhea after HSCT is still subjected to endoscopy and histological findings. The research for a reliable biomarker for gut GvHD might allow an early diagnosis of this condition and a consequent prompt treatment that could reduce unfavorable outcomes. Recently, fecal calprotectin was reported as reliable marker of gut involvement. We would evaluate if serum instead of fecal calprotectin could be considered a possible biomarker of gut GvHD. Serum calprotectin was measured in a cohort of 54 patients submitted to allogeneic stem cell transplantation using ELISA assay. For a subset of 21 patients, calprotectin serum levels were compared with fecal calprotectin detection. Contrary to fecal calprotectin, we found only a trend to high level of serum calprotectin for GvHD development and gut involvement, but statistical difference was not reached. Fecal but not serum calprotectin could be considered as possible biomarker for gut GvHD.
胃肠道移植物抗宿主病（GvHD）是干细胞移植后一种危及生命的并发症。肠道GvHD与造血干细胞移植（HSCT）后其他腹泻原因之间的鉴别诊断仍依赖于内镜检查和组织学检查结果。寻找肠道GvHD可靠生物标志物的研究可能有助于早期诊断该疾病，并因此及时进行治疗，从而降低不良后果。最近，粪便钙卫蛋白被报道为肠道受累的可靠标志物。我们将评估血清钙卫蛋白而非粪便钙卫蛋白是否可被视为肠道GvHD的一种可能生物标志物。使用酶联免疫吸附测定（ELISA）法对54例接受异基因干细胞移植的患者进行血清钙卫蛋白检测。对其中21例患者的子集，将血清钙卫蛋白水平与粪便钙卫蛋白检测结果进行比较。与粪便钙卫蛋白相反，我们发现血清钙卫蛋白水平仅在GvHD发生和肠道受累时有升高趋势，但未达到统计学差异。粪便而非血清钙卫蛋白可被视为肠道GvHD的一种可能生物标志物。
